{"url_path":"/sec/rnaz/8-k/2026-06-03/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1829635/0001104659-26-069810-index.html","accession_number":"0001104659-26-069810","cik":"0001829635","ticker":"RNAZ","issuer_name":"Transcode Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1829635/0001104659-26-069810-index.html","primary_entity_key":"0001829635","primary_entity_name":"Transcode Therapeutics, Inc."},"word_count":77,"has_tables":true,"body_markdown":"**Item 9.01 Financial Statements and Exhibits.**\n\n \n\n(d) Exhibits\n\n \n\nExhibit No.\nDescription\n\n \n \n\n[99.1](tm2616719d1_ex99-1.htm)\n[Press Release, dated June 3, 2026](tm2616719d1_ex99-1.htm)\n\n \n \n\n104\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\n \n\n \n\n**SIGNATURE**\n\n \n\nPursuant to the requirements\nof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto\nduly authorized.\n\n \n\n \n**TransCode Therapeutics, Inc.**\n\n \n \n\nDate: June 3, 2026\nBy:\n/s/ Philippe Calais\n\n \n \nPhilippe Calais\n\n \n \nChief Executive Officer"}